Market research
1177.HK Sino Biopharmaceutical Limited
Current ticker: 1177.HK
HK HKD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 89B
- P/E ratio
- 33.2
- Analyst target
- 8.4603
- Dividend yield
- 2.0%
- Beta
- 0.61
Profile
Instrument facts
- Exchange
- HK
- Currency
- HKD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- KYG8167W1380
- Market cap
- 89B
- P/E ratio
- 33.2
- Analyst target
- 8.4603
- Dividend yield
- 2.0%
- Beta
- 0.61
About
About Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, culmerciclib capsule under Saitanxin brand, zongertinib tablets under Hernexeos brand, rovadicitinib tablet under Anxu brand,rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anqixin. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH3906; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD208. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Research context
Sino Biopharmaceutical Limited appears in PyInvesting’s Hong Kong Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- HKD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 1177.HK discussion.
5 years, 6 months ago
Sino Biopharmaceutical Limited is currently in a long term downtrend where the price is trading 11.4% below its 200 day moving average.
From a valuation standpoint, the stock is 95.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.2.
Sino Biopharmaceutical Limited's total revenue rose by 12.4% to $6B since the same quarter in the previous year.
Its net income has increased by 104.0% to $921M since the same quarter in the previous year.
Finally, its free cash flow fell by 70.8% to $2B since the same quarter in the previous year.
Based on the above factors, Sino Biopharmaceutical Limited gets an overall score of 3/5.